-
1
-
-
35548956906
-
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma
-
Abubaker J., Bavi P.P., Al-Harbi S., Siraj A.K., Al-Dayel F., Uddin S. and Al-Kuraya K. (2007). PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 21, 2368-2370.
-
(2007)
Leukemia
, vol.21
, pp. 2368-2370
-
-
Abubaker, J.1
Bavi, P.P.2
Al-Harbi, S.3
Siraj, A.K.4
Al-Dayel, F.5
Uddin, S.6
Al-Kuraya, K.7
-
3
-
-
3042785708
-
Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections
-
Atkins D., Reiffen K.A., Tegtmeier C.L., Winther H., Bonato M.S. and Störkel S. (2004). Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 52, 893-901.
-
(2004)
J. Histochem. Cytochem
, vol.52
, pp. 893-901
-
-
Atkins, D.1
Reiffen, K.A.2
Tegtmeier, C.L.3
Winther, H.4
Bonato, M.S.5
Störkel, S.6
-
4
-
-
35948964043
-
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
-
Barbareschi M., Buttitta F., Felicioni L., Cotrupi S., Barassi F., Del Grammastro M., Ferro A., Dalla Palma P., Galligioni E. and Marchetti A. (2007). Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Cancer. Res. 13, 6064-6069.
-
(2007)
Clin. Cancer. Res
, vol.13
, pp. 6064-6069
-
-
Barbareschi, M.1
Buttitta, F.2
Felicioni, L.3
Cotrupi, S.4
Barassi, F.5
del Grammastro, M.6
Ferro, A.7
Dalla, P.P.8
Galligioni, E.9
Marchetti, A.10
-
5
-
-
53949104487
-
Anti-epidermal growth factor receptor strategies for advanced breast cancer
-
Campos S.M. (2008). Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 26, 757-768.
-
(2008)
Cancer Invest
, vol.26
, pp. 757-768
-
-
Campos, S.M.1
-
6
-
-
40949121882
-
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype
-
Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M. and Nielsen T.O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin. Cancer. Res. 14, 1368-1376.
-
(2008)
Clin. Cancer. Res
, vol.14
, pp. 1368-1376
-
-
Cheang, M.C.1
Voduc, D.2
Bajdik, C.3
Leung, S.4
McKinney, S.5
Chia, S.K.6
Perou, C.M.7
Nielsen, T.O.8
-
7
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P. and Saltz L.B. (2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803-1810.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
Shah, M.4
Schwartz, G.K.5
Tse, A.6
Hamilton, A.7
Pan, D.8
Schrag, D.9
Schwartz, L.10
Klimstra, D.S.11
Fridman, D.12
Kelsen, D.P.13
Saltz, L.B.14
-
8
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
Ciardiello F. and Tortora G. (2008). EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174.
-
(2008)
N. Engl. J. Med
, vol.358
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
9
-
-
4043055279
-
BRAF alterations are associated with complex mutational profiles in malignant melanoma
-
Daniotti M., Oggionni M., Ranzani T., Vallacchi V., Campi V., Di Stasi D., Torre G.D., Perrone F., Luoni C., Suardi S., Frattini M., Pilotti S., Anichini A., Tragni G., Parmiani G., Pierotti M.A. and Rodolfo M. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968-5977.
-
(2004)
Oncogene
, vol.23
, pp. 5968-5977
-
-
Daniotti, M.1
Oggionni, M.2
Ranzani, T.3
Vallacchi, V.4
Campi, V.5
di Stasi, D.6
Torre, G.D.7
Perrone, F.8
Luoni, C.9
Suardi, S.10
Frattini, M.11
Pilotti, S.12
Anichini, A.13
Tragni, G.14
Parmiani, G.15
Pierotti, M.A.16
Rodolfo, M.17
-
10
-
-
35348908314
-
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
-
Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L.L., Cavalli F. and Mazzucchelli L. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139-1145.
-
(2007)
Br. J. Cancer
, vol.97
, pp. 1139-1145
-
-
Frattini, M.1
Saletti, P.2
Romagnani, E.3
Martin, V.4
Molinari, F.5
Ghisletta, M.6
Camponovo, A.7
Etienne, L.L.8
Cavalli, F.9
Mazzucchelli, L.10
-
11
-
-
33745660509
-
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
-
Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R. and Hanby A. (2006). Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49, 22-34.
-
(2006)
Histopathology
, vol.49
, pp. 22-34
-
-
Fulford, L.G.1
Easton, D.F.2
Reis-Filho, J.S.3
Sofronis, A.4
Gillett, C.E.5
Lakhani, S.R.6
Hanby, A.7
-
12
-
-
65249139954
-
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
-
Gonzalez-Angulo A.M., Stemke-Hale K., Palla S.L., Carey M., Agarwal R., Meric-Berstam F., Traina T.A., Hudis C., Hortobagyi G.N., Gerald W.L., Mills G.B. and Hennessy B.T. (2009). Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin. Cancer Res. 15, 2472-2478.
-
(2009)
Clin. Cancer Res
, vol.15
, pp. 2472-2478
-
-
Gonzalez-Angulo, A.M.1
Stemke-Hale, K.2
Palla, S.L.3
Carey, M.4
Agarwal, R.5
Meric-Berstam, F.6
Traina, T.A.7
Hudis, C.8
Hortobagyi, G.N.9
Gerald, W.L.10
Mills, G.B.11
Hennessy, B.T.12
-
13
-
-
35248889408
-
EGFR associated expression profiles vary with breast tumor subtype
-
Hoadley K.A., Weigman V.J., Fan C., Sawyer L.R., He X., Troester M.A., Sartor C.I., Rieger-House T., Bernard P.S., Carey L.A. and Perou C.M. (2007). EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8, 258.
-
(2007)
BMC Genomics
, vol.8
, pp. 258
-
-
Hoadley, K.A.1
Weigman, V.J.2
Fan, C.3
Sawyer, L.R.4
He, X.5
Troester, M.A.6
Sartor, C.I.7
Rieger-House, T.8
Bernard, P.S.9
Carey, L.A.10
Perou, C.M.11
-
14
-
-
33745058415
-
Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas
-
Kersting C., Packeisen J., Leidinger B., Brandt B., von Wasielewski R., Winkelmann W., van Diest P.J., Gosheger G. and Buerger H. (2006). Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J. Clin. Pathol. 59, 585-590.
-
(2006)
J. Clin. Pathol
, vol.59
, pp. 585-590
-
-
Kersting, C.1
Packeisen, J.2
Leidinger, B.3
Brandt, B.4
von Wasielewski, R.5
Winkelmann, W.6
van Diest, P.J.7
Gosheger, G.8
Buerger, H.9
-
15
-
-
78650630648
-
Candidate predictive biomarkers of cetuximab benefit in triplenegative breast cancer
-
(suppl; abstr 1056)
-
Khambata-Ford S., O'Shaughnessy J. and Brickman D. (2010). Candidate predictive biomarkers of cetuximab benefit in triplenegative breast cancer. J. Clin. Oncol. 28, 15s (suppl; abstr 1056).
-
(2010)
J. Clin. Oncol
, vol.28
-
-
Khambata-Ford, S.1
O'Shaughnessy, J.2
Brickman, D.3
-
16
-
-
33747819585
-
Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neuoverexpressing phenotypes
-
Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B. and Gong G. (2006). Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum. Pathol. 37, 1217-1226.
-
(2006)
Hum. Pathol
, vol.37
, pp. 1217-1226
-
-
Kim, M.J.1
Ro, J.Y.2
Ahn, S.H.3
Kim, H.H.4
Kim, S.B.5
Gong, G.6
-
17
-
-
3142559728
-
Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation
-
Langner C., Ratschek M., Rehak P., Schips L. and Zigeuner R. (2004). Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J. Clin. Pathol. 57, 773-775.
-
(2004)
J. Clin. Pathol
, vol.57
, pp. 773-775
-
-
Langner, C.1
Ratschek, M.2
Rehak, P.3
Schips, L.4
Zigeuner, R.5
-
18
-
-
80051592124
-
Combinatorial effects of lapatinib and rapamycin in triplenegative breast cancer cells
-
Liu T., Yacoub R., Taliaferro-Smith L.D., Sun S.Y., Graham T.R., Dolan R., Lobo C., Tighiouart M., Yang L., Adams A. and O'Regan R.M. (2011). Combinatorial effects of lapatinib and rapamycin in triplenegative breast cancer cells. Mol. Cancer Ther. 10, 1460-1469.
-
(2011)
Mol. Cancer Ther
, vol.10
, pp. 1460-1469
-
-
Liu, T.1
Yacoub, R.2
Taliaferro-Smith, L.D.3
Sun, S.Y.4
Graham, T.R.5
Dolan, R.6
Lobo, C.7
Tighiouart, M.8
Yang, L.9
Adams, A.10
O'Regan, R.M.11
-
19
-
-
74049107249
-
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
-
López-Knowles E., O'Toole S.A., McNeil C.M., Qiu M.R., Crea P., Daly R.J., Musgrove E.A. and Sutherland R.L. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer 126, 1121-1131.
-
(2010)
Int. J. Cancer
, vol.126
, pp. 1121-1131
-
-
López-Knowles, E.1
O'Toole, S.A.2
McNeil, C.M.3
Qiu, M.R.4
Crea, P.5
Daly, R.J.6
Musgrove, E.A.7
Sutherland, R.L.8
-
20
-
-
65849527304
-
An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
-
Martin V., Mazzucchelli L. and Frattini M. (2009). An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J. Clin. Pathol. 62, 314-324.
-
(2009)
J. Clin. Pathol
, vol.62
, pp. 314-324
-
-
Martin, V.1
Mazzucchelli, L.2
Frattini, M.3
-
21
-
-
63949084084
-
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
-
Molinari F., Martin V., Saletti P., De Dosso S., Spitale A., Camponovo A., Bordoni A., Crippa S., Mazzucchelli L. and Frattini M. (2009). Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br. J. Cancer 100, 1087-1094.
-
(2009)
Br. J. Cancer
, vol.100
, pp. 1087-1094
-
-
Molinari, F.1
Martin, V.2
Saletti, P.3
de Dosso, S.4
Spitale, A.5
Camponovo, A.6
Bordoni, A.7
Crippa, S.8
Mazzucchelli, L.9
Frattini, M.10
-
22
-
-
4143150688
-
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
-
Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Gown A.M., Gilks C.B., van de Rijn M. and Perou C.M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367-5374.
-
(2004)
Clin. Cancer Res
, vol.10
, pp. 5367-5374
-
-
Nielsen, T.O.1
Hsu, F.D.2
Jensen, K.3
Cheang, M.4
Karaca, G.5
Hu, Z.6
Hernandez-Boussard, T.7
Livasy, C.8
Cowan, D.9
Dressler, L.10
Akslen, L.A.11
Ragaz, J.12
Gown, A.M.13
Gilks, C.B.14
van de Rijn, M.15
Perou, C.M.16
-
23
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., Zakowski M.F., Heelan R.T., Kris M.G. and Varmus H.E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
Miller, V.A.4
Pan, Q.5
Ladanyi, M.6
Zakowski, M.F.7
Heelan, R.T.8
Kris, M.G.9
Varmus, H.E.10
-
24
-
-
67650498979
-
Triple negative breast cancer: A study from the point of view of basal CK5/6 and HER-1
-
Pintens S., Neven P., Drijkoningen M., Van Belle V., Moerman P., Christiaens M.R., Smeets A., Wildiers H. and Vanden Bempt I. (2009). Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J. Clin. Pathol. 62, 624-628.
-
(2009)
J. Clin. Pathol
, vol.62
, pp. 624-628
-
-
Pintens, S.1
Neven, P.2
Drijkoningen, M.3
van Belle, V.4
Moerman, P.5
Christiaens, M.R.6
Smeets, A.7
Wildiers, H.8
van den Bempt, I.9
-
25
-
-
67049119497
-
Basal-like breast carcinoma: From expression profiling to routine practice
-
Rakha E. and Reis-Filho J.S. (2009). Basal-like breast carcinoma: from expression profiling to routine practice. Arch. Pathol. Lab. Med. 133, 860-868.
-
(2009)
Arch. Pathol. Lab. Med
, vol.133
, pp. 860-868
-
-
Rakha, E.1
Reis-Filho, J.S.2
-
26
-
-
33644695272
-
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation
-
Rakha E.A., Putti T.C., Abd El-Rehim D.M., Paish C., Green A.R., Powe D.G., Lee A.H., Robertson J.F. and Ellis I.O. (2006). Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 208, 495-506.
-
(2006)
J. Pathol
, vol.208
, pp. 495-506
-
-
Rakha, E.A.1
Putti, T.C.2
Abd, E.-R.D.M.3
Paish, C.4
Green, A.R.5
Powe, D.G.6
Lee, A.H.7
Robertson, J.F.8
Ellis, I.O.9
-
28
-
-
33745653114
-
Metaplastic breast carcinomas are basal-like tumours
-
Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T., Nesland J.M., Pereira E.M., Lakhani S.R. and Schmitt F.C. (2006). Metaplastic breast carcinomas are basal-like tumours. Histopathology. 49, 10-21.
-
(2006)
Histopathology
, vol.49
, pp. 10-21
-
-
Reis-Filho, J.S.1
Milanezi, F.2
Steele, D.3
Savage, K.4
Simpson, P.T.5
Nesland, J.M.6
Pereira, E.M.7
Lakhani, S.R.8
Schmitt, F.C.9
-
29
-
-
33645072444
-
Prognostic significance of basallike phenotype and fascin expression in node-negative invasive breast carcinomas
-
Rodríguez-Pinilla S.M., Sarrió D., Honrado E., Hardisson D., Calero F., Benitez J. and Palacios J. (2006). Prognostic significance of basallike phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12, 1533-1539.
-
(2006)
Clin. Cancer Res
, vol.12
, pp. 1533-1539
-
-
Rodríguez-Pinilla, S.M.1
Sarrió, D.2
Honrado, E.3
Hardisson, D.4
Calero, F.5
Benitez, J.6
Palacios, J.7
-
30
-
-
20144387695
-
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
-
Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmström P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A. and Parsons R. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559.
-
(2005)
Cancer Res
, vol.65
, pp. 2554-2559
-
-
Saal, L.H.1
Holm, K.2
Maurer, M.3
Memeo, L.4
Su, T.5
Wang, X.6
Yu, J.S.7
Malmström, P.O.8
Mansukhani, M.9
Enoksson, J.10
Hibshoosh, H.11
Borg, A.12
Parsons, R.13
-
31
-
-
37549020704
-
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
-
Saal L.H., Gruvberger-Saal S.K., Persson C., Lövgren K., Jumppanen M., Staaf J., Jönsson G., Pires M.M., Maurer M, Holm K., Koujak S., Subramaniyam S., Vallon-Christersson J., Olsson H., Su T., Memeo L., Ludwig T., Ethier S.P., Krogh M., Szabolcs M., Murty V.V., Isola J., Hibshoosh H., Parsons R. and Borg A. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 40, 102-107.
-
(2008)
Nat. Genet
, vol.40
, pp. 102-107
-
-
Saal, L.H.1
Gruvberger-Saal, S.K.2
Persson, C.3
Lövgren, K.4
Jumppanen, M.5
Staaf, J.6
Jönsson, G.7
Pires, M.M.8
Maurer, M.9
Holm, K.10
Koujak, S.11
Subramaniyam, S.12
Vallon-Christersson, J.13
Olsson, H.14
Su, T.15
Memeo, L.16
Ludwig, T.17
Ethier, S.P.18
Krogh, M.19
Szabolcs, M.20
Murty, V.V.21
Isola, J.22
Hibshoosh, H.23
Parsons, R.24
Borg, A.25
more..
-
32
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies
-
Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S. and Bardelli A. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res. 69, 1851-1857.
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
Veronese, S.4
Nichelatti, M.5
Artale, S.6
di Nicolantonio, F.7
Saletti, P.8
de Dosso, S.9
Mazzucchelli, L.10
Frattini, M.11
Siena, S.12
Bardelli, A.13
-
33
-
-
70349939382
-
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer
-
Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J. and Bardelli A. (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101, 1308-1324.
-
(2009)
J. Natl. Cancer Inst
, vol.101
, pp. 1308-1324
-
-
Siena, S.1
Sartore-Bianchi, A.2
di Nicolantonio, F.3
Balfour, J.4
Bardelli, A.5
-
34
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lønning P. and Børresen-Dale A.L.(2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874.
-
(2001)
Proc. Natl. Acad. Sci. USA
, vol.98
, pp. 10869-10874
-
-
Sørlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
Hastie, T.7
Eisen, M.B.8
van de Rijn, M.9
Jeffrey, S.S.10
Thorsen, T.11
Quist, H.12
Matese, J.C.13
Brown, P.O.14
Botstein, D.15
Eystein, L.P.16
Børresen-Dale, A.L.17
-
35
-
-
0037478605
-
Repeated observation of breast tumor subtypes in independent gene expression data sets
-
Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lønning P.E., Brown P.O., Børresen-Dale A.L. and Botstein D. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl. Acad. Sci. USA 100, 8418-8423.
-
(2003)
Proc Natl. Acad. Sci. USA
, vol.100
, pp. 8418-8423
-
-
Sorlie, T.1
Tibshirani, R.2
Parker, J.3
Hastie, T.4
Marron, J.S.5
Nobel, A.6
Deng, S.7
Johnsen, H.8
Pesich, R.9
Geisler, S.10
Demeter, J.11
Perou, C.M.12
Lønning, P.E.13
Brown, P.O.14
Børresen-Dale, A.L.15
Botstein, D.16
-
36
-
-
54249098184
-
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal for an European quality assurance program
-
van Krieken J.H., Jung A., Kirchner T., Carneiro F., Seruca R., Bosman F.T., Quirke P., Fléjou J.F., Plato Hansen T, de Hertogh G., Jares P., Langner C., Hoefler G., Ligtenberg M., Tiniakos D., Tejpar S., Bevilacqua G. and Ensari A. (2008). KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453, 417-431.
-
(2008)
Virchows Arch
, vol.453
, pp. 417-431
-
-
van Krieken, J.H.1
Jung, A.2
Kirchner, T.3
Carneiro, F.4
Seruca, R.5
Bosman, F.T.6
Quirke, P.7
Fléjou, J.F.8
Plato, H.T.9
de Hertogh, G.10
Jares, P.11
Langner, C.12
Hoefler, G.13
Ligtenberg, M.14
Tiniakos, D.15
Tejpar, S.16
Bevilacqua, G.17
Ensari, A.18
-
37
-
-
34248147439
-
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: The EGFR fluorescence in situ hybridization assay
-
Varella-Garcia M. (2006). Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn. Pathol. 1, 19.
-
(2006)
Diagn. Pathol
, vol.1
, pp. 19
-
-
Varella-Garcia, M.1
-
38
-
-
73349140213
-
EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer
-
Varella-Garcia M., Diebold J., Eberhard D.A., Geenen K., Hirschmann A., Kockx M., Nagelmeier I., Rüschoff J., Schmitt M., Arbogast S. and Cappuzzo F. (2009). EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 62, 970-977.
-
(2009)
J. Clin. Pathol
, vol.62
, pp. 970-977
-
-
Varella-Garcia, M.1
Diebold, J.2
Eberhard, D.A.3
Geenen, K.4
Hirschmann, A.5
Kockx, M.6
Nagelmeier, I.7
Rüschoff, J.8
Schmitt, M.9
Arbogast, S.10
Cappuzzo, F.11
-
39
-
-
84859314389
-
-
Registry of clinical trials
-
www.clinicaltrial.gov; Registry of clinical trials.
-
-
-
-
40
-
-
84859348994
-
-
COSMIC: Catalogue Of Somatic Mutations In Cancer
-
www.sanger.ac.uk/genetics/CGP/cosmic; COSMIC: Catalogue Of Somatic Mutations In Cancer.
-
-
-
|